221 results about "Pathophysiology" patented technology

The invention includes a novel method and system to achieve leaflet coaptation in a cardiac valve percutaneously by creation of neochordae to prolapsing valve segments. This technique is especially useful in cases of ruptured chordae, but may be utilized in any segment of prolapsing leaflet. The technique described herein has the additional advantage of being adjustable in the beating heart. This allows tailoring of leaflet coaptation height under various loading conditions using image-guidance, such as echocardiography. This offers an additional distinct advantage over conventional open-surgery placement of artificial chordae. In traditional open surgical valve repair, chord length must be estimated in the arrested heart and may or may not be correct once the patient is weaned from cardiopulmonary bypass. The technique described below also allows for placement of multiple artificial chordae, as dictated by the patient's pathophysiology.

A medical device for interposition between a first flow path and at least one second flow path is provided. The device includes a first surface facing toward the opening of at least one second flow path; and a second surface facing away from the opening of at least one second flow path. When the device is in the operative position, it extends less than the complete circumference of the first flow path and substantially covers the opening of at least one second flow path. The device contains one or more surface features to facilitate chronic implantation. The device further has one or more characteristic porosities. Different configurations are indicated depending on the pathophysiology being treated and dictate the characteristic porosity of the device. In some, cases blood is prevented from reaching the second flow path and in other cases, particulates traveling within the blood are prevented from reaching the second flow path. Methods of preventing emboli or blood flow into the second flow path are also provided. Methods and devices for delivery are also provided.

This invention defines a novel method for treatment of several neurological diseases and pathophysiologically related symptomology, said diseases including peripheral neuropathies, secondary symptomology of diabetes, Alzheimer's disease, Parkinson's disease, alcoholic polyneuropathy and age-onset symptomology, as well as analogous veterinary disease states. An opportunity exists for pharmacological intervention in some neurological diseases by use of water soluble, small molecular weight primary amine agents and chemical derivatives thereof. Examples of such primary pharmacological agents include 4-aminobenzoic acid and derivatives thereof. The present invention also includes: (1) oral use of optional non-absorbable polyamine polymeric co-agents such as chitosan, (2) oral use of optional known antioxidant co-agents and nutritional factors related thereto, and (3) use of the primary agents and co-agents noted above in optional combination with medicaments recognized as effective for treatment of the diseases addressed herein or symptoms thereof.

A system and method for organization and analysis of complex and dynamically interactive time series is disclosed. One example comprises a processor based system for relational analysis of physiologic signals for providing early recognition of catastrophic and pathologic events such as pathophysiologic divergence. The processor is programmed to identify pathophysiologic divergence of at least one of first and second physiologic parameters in relationship to the other and to output an indication of the divergence. An object-based method of iterative relational processing waveform fragments in the time domain is described wherein each more complex waveform object inherits the characteristics of the waveform objects from which it is derived. The first physiologic parameter can be the amplitude and frequency of the variation in chest wall impedance or nasal pressure and the second parameter can be a measure or indication of the arterial oxygen saturation.

An automated system and method for diagnosing and monitoring respiratory insufficiency and outcomes thereof is described. A plurality of monitoring sets is retrieved from a database. Each of the monitoring sets include recorded measures relating to patient information recorded on a substantially continuous basis. A patient status change is determined by comparing at least one recorded measure from each of the monitoring sets to at least one other recorded measure. Both recorded measures relate to the same type of patient information. Each patient status change is tested against an indicator threshold corresponding to the same type of patient information as the recorded measures which were compared. The indicator threshold corresponds to a quantifiable physiological measure of a pathophysiology indicative of respiratory insufficiency.

A patient apparatus is configured to receive and analyze information regarding patient compliance with anticoagulation medication and self-test coagulation regimens related to anticoagulation therapy. In addition, a patient apparatus is configured to receive data from a patient, including physiological data, pathophysiological data, biological data, psychological data, neuropsychological data, and/or behavioral data. Utilizing the received patient data, a patient apparatus can modify a warfarin regimen using an algorithm contained within the apparatus. The apparatus can communicate the modified warfarin regimen to the patient and to third parties, such as remotely located healthcare providers. In addition, the apparatus can prompt a patient when to perform a self-test and can prompt a patient to seek immediate medical attention, or to directly contact medical help, when so warranted.

A flexible membrane of piezoelectric material sized to be supported by and to conform to the eardrum. Electrodes on the membrane allow the membrane to function as an audio transducer stimulating the eardrum with an audio signal or detecting audio signals at the eardrum. Applications may include detecting a variety of pathophysiological and biomechanical features of the tissues of the tympanic membrane and regional integrated anatomy, detecting audio, physical and biological signals, and/or delivery a variety of therapeutic modalities.

Fibrosis arises as part of a wound healing response that maintains organ integrity following catastrophic tissue damage, but can also contribute to a variety of human pathologies, including liver cirrhosis. The invention demonstrates that cellular senescence acts to limit the fibrogenic response to tissue damage, thereby establishing a role for the senescence program in pathophysiological settings beyond cancer. Accordingly, the methods of the invention relate to modulating cellular senescence in disease tissue that have elevated numbers of senescent cells, such as in fibrotic tissues.

Compounds having quinone and quinone analogs useful for pharmaceutical preparations have now been found which inhibit cysteine proteases, in particular, caspases and 3C-cysteine proteases. The cysteine protease inhibitors of the present invention can be identified by their mode of action in disrupting the ability of cysteine proteases and, in particular, caspases to cleave a peptide chain. These compounds are useful in inhibiting cysteine protease or cysteine protease-like proteins and for treating infections diseases or physiopathological diseases or disorders attributed to the presence of excessive or insufficient levels of cysteine proteases.

Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK₁) receptor. The compounds have the general formula (I):

A stent comprises a tubular base body which is open on the front sides thereof and has a peripheral wall that is at least partially covered with a coating system consisting of at least one polymer carrier and at least one pharmacologically active substance, which is released into the surrounding tissue once the stent has been implanted in the human or animal body. The invention creates a coating system which enables an optimum local application of the active ingredient. A concentration of the substance, a morphological structure of the carrier(s), a material modification of the carrier(s), and/or a layer thickness of the carrier(s), are predetermined in the longitudinal direction of the stent, in such a way that the elution varies locally in the longitudinal direction of the stent and is determined according to the pathophysiological and/or rheological conditions to be expected during the application.

The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example misfolded proteins like amyloid B and advanced glycation-end-products.

The invention encompasses a novel method of treating inflammatory disease, such as rheumatoid arthritis, and novel methods of identifying and screening for drugs useful in the treatment of inflammatory diseases and their clinical symptoms. The inventors have made the discovery that the activity of HIF-1α, a transcription regulator known to have an effect on some cancers, has a significant impact on the pathophysiology of rheumatoid arthritis. The symptoms of an inflammatory disease, such as rheumatoid arthritis, may be alleviated by administering a compound that inhibits the activity of HIF-1α.

The application relates to a culture medium for nasopharyngeal carcinoma organs, and methods for culturing and identifying the nasopharyngeal carcinoma organs. According to the culture and growth characteristics of nasopharyngeal carcinoma-derived cells, a variety of cytokine components are selected and blended according to a certain ratio; the contents of cytokines and signal pathway regulatory factors in the culture medium are suitable; the nasopharyngeal carcinoma cells can effectively form organoids in a three-dimensional (3D) environment. The methods for culturing and identifying the nasopharyngeal carcinoma organs as well as the unique culture medium for the nasopharyngeal carcinoma organs can be used for successfully and stably culturing the nasopharyngeal carcinoma organs which have pathophysiological features and genotypes being highly consistent with those of the parental tumor and have high similar form of organization.